← Back to Search

FoundationOne Testing for Rare Cancers (TRACK Trial)

N/A

Recruiting

Led By Vivek Subbiah, M.D.

Research Sponsored by TargetCancer Foundation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

TRACK Trial Summary

This trial will test whether patients with rare tumors can benefit from treatment based on their NGS results.

Eligible Conditions

Rare Cancers
Bile Duct Cancer
Cancer of Unknown Primary

TRACK Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.

Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.

Secondary outcome measures

Comparison of Tumor Biomarker Profiling to Treatment Outcome.

TRACK Trial Design

3Treatment groups

Active Control

Group I: Other remaining rare cancers (solid tumors & lymphomas)Active Control1 Intervention

Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).

Group II: Cancer of Unknown Primary (CUP)Active Control1 Intervention

Eligible patients with cancer of unknown primary site (CUP).

Group III: CholangiocarcinomaActive Control1 Intervention

Eligible patients that present with Cholangiocarcinoma.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

TargetCancer FoundationLead Sponsor

1 Previous Clinical Trials

8 Total Patients Enrolled

Foundation MedicineIndustry Sponsor

32 Previous Clinical Trials

15,792 Total Patients Enrolled

Vivek Subbiah, M.D.Principal InvestigatorThe University of Texas MD Anderson Cancer Center (MDACC)

Media Library

Other remaining rare cancers (solid tumors & lymphomas) Clinical Trial Eligibility Overview. Trial Name: NCT04504604 — N/A

Rare Cancers Research Study Groups: Other remaining rare cancers (solid tumors & lymphomas), Cancer of Unknown Primary (CUP), Cholangiocarcinoma

Rare Cancers Clinical Trial 2023: Other remaining rare cancers (solid tumors & lymphomas) Highlights & Side Effects. Trial Name: NCT04504604 — N/A

Other remaining rare cancers (solid tumors & lymphomas) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04504604 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current size of the cohort undergoing this experiment?

"Correct. The information available on clinicaltrials.gov confirms that this medical trial, which was first posted in October 1st 2020, is still actively seeking participants. Altogether, 400 patients need to be recruited from one study centre."

Answered by AI

Is enrollment for this clinical experiment available at the present time?

"According to clinicaltrials.gov, this investigation is actively looking for participants and was first published on October 1st 2020 before being revised most recently on October 21st 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

2020. "TCF-001 TRACK (Target Rare Cancer Knowledge) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04504604.